Mechanism Research Progress of Traditional Chinese Medicine in Prevention and Treatment of Cholangiocarcinoma

LYU Yanlin; PAN Yaozhen

doi:10.3971/j.issn.1000-8578.2023.23.0807

Cancer Research on Prevention and Treatment > 2023 > 50(12): 1180-1184. > DOI: 10.3971/j.issn.1000-8578.2023.23.0807

LYU Yanlin, PAN Yaozhen. Mechanism Research Progress of Traditional Chinese Medicine in Prevention and Treatment of Cholangiocarcinoma[J]. Cancer Research on Prevention and Treatment, 2023, 50(12): 1180-1184. DOI: 10.3971/j.issn.1000-8578.2023.23.0807

Citation:

PDF (1881 KB)

Mechanism Research Progress of Traditional Chinese Medicine in Prevention and Treatment of Cholangiocarcinoma

LYU Yanlin^1,,
PAN Yaozhen^{1, 2, , ,}

1.
Department of Hepatobiliary Surgery, The Affiliated Cancer Hospital of Guizhou Medical University, Guiyang 550000, China
2.
School of Clinical Medicine, Guizhou Medical University, Guiyang 550000, China

Funding:

National Natural Science Foundation of China 81960431

More Information

Corresponding author:
PAN Yaozhen, E-mail: panyaozhen112@163.com
Received Date: July 26, 2023
Revised Date: August 31, 2023
Available Online: January 12, 2024

Graphical Abstract

Abstract

Abstract

Cholangiocarcinoma is a bile duct adenocarcinoma derived from the bile duct epithelium. Current treatment strategies for cholangiocarcinoma include surgery, chemotherapy, and radiotherapy. Surgical treatment is the first choice for all subtypes of cholangiocarcinoma. However, cholangiocarcinoma has the characteristics of high malignancy, easy recurrence after surgery, and low 5-year survival rates. Recent studies have found that many traditional Chinese medicines exhibit excellent anti-tumor effects in the treatment of various cancers, including cholangiocarcinoma. These medicines have advantages, such as low prices and abundant reserves, and are considered as an effective and safe complementary and alternative therapy for the treatment of cholangiocarcinoma. This article aims to review the effects of traditional Chinese medicine on cholangiocarcinoma from different aspects and levels in recent years. Results will provide new ideas for the prevention and treatment of cholangiocarcinoma.
- Cholangiocarcinoma,
- Traditional Chinese medicine,
- Anti-tumor

FullText(HTML)

Competing interests: The authors declare that they have no competing interests.

References (30)

References

[1]	Loeuillard E, Conboy CB, Gores GJ, et al. Immunobiology of cholangiocarcinoma[J]. JHEP Rep, 2019, 1(4): 297-311. doi: 10.1016/j.jhepr.2019.06.003
[2]	Sirica AE, Gores GJ, Groopman JD, et al. Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances[J]. Hepatology, 2019, 69(4): 1803-1815. doi: 10.1002/hep.30289
[3]	Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021[J]. CA Cancer J Clin, 2021, 71(1): 7-33. doi: 10.3322/caac.21654
[4]	Ilyas SL, Affo S, Goyal L, et al. Cholangiocarcinoma - novel biological insights and therapeutic strategies[J]. Nat Rev Clin Oncol, 2023, 20(7): 470-486. doi: 10.1038/s41571-023-00770-1
[5]	Brindley P, Bachini M, Ilyas S, et al. Cholangiocarcinoma[J]. Nat Rev Dis Primers, 2021, 7(1): 65. doi: 10.1038/s41572-021-00300-2
[6]	Tan EK, Rosen CB, Heimbach JK, et al. Living Donor Liver Transplantation for Perihilar Cholangiocarcinoma: Outcomes and Complications[J]. J Am Coll Surg, 2020, 231(1): 98-110. doi: 10.1016/j.jamcollsurg.2019.12.037
[7]	Lim KH, Han SW, Oh DY, et al. Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer[J]. Oncology, 2012, 83(2): 57-66. doi: 10.1159/000338795
[8]	Goyal L, Meric-Bernstam F, Hollebecque A, et al. Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma[J]. N Engl J Med, 2023, 388(3): 228-239. doi: 10.1056/NEJMoa2206834
[9]	Moris D, Palta M, Kim C, et al. Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians[J]. CA Cancer J Clin, 2023, 73(2): 198-222. doi: 10.3322/caac.21759
[10]	陈锦芳, 邬世威, 胡兵. 抗肿瘤中药网络药理学研究进展分析[J]. 中医药学报, 2023, 51(1): 115-119. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYXB202301023.htm Chen JF, Wu SW, Hu B. Anti-tumor medicine network pharmacology research progress analysis [J]. Zhong Yi Yao Xue Bao, 2023, 51(1) : 115-119. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYXB202301023.htm
[11]	Wang Y, Dong B, Xue W, et al. Anticancer Effect of Radix Astragali on Cholangiocarcinoma In Vitro and Its Mechanism via Network Pharmacology[J]. Med Sci Monit, 2020, 26: e921162.
[12]	Liu JJ, Xu Y, Chen S, et al. The mechanism of Yinchenhao decoction in treating obstructive-jaundice-induced liver injury based on Nrf2 signaling pathway[J]. World J Gastroenterol, 2022, 28(32): 4635-4648. doi: 10.3748/wjg.v28.i32.4635
[13]	刘军舰, 陈帅, 袁红霞, 等. 基于Nr f2信号通路探讨茵陈蒿汤对阻塞性黄疸大鼠肾氧化应激损伤的影响及其作用机制[J]. 临床肝胆病杂志, 2023, 39(5): 1126-1133. doi: 10.3969/j.issn.1001-5256.2023.05.019 Liu JJ, Chen S, Yuan HX, et al. Effect of Yinchenhao Decoction on renal oxidative stress injury in rats with obstructive jaundice based on Nrf2 signaling pathway and its mechanism[J]. Lin Chuang Gan Dan Bing Za Zhi, 2023, 39(5): 1126-1133. doi: 10.3969/j.issn.1001-5256.2023.05.019
[14]	Chen Z, Lin T, Liao X, et al. Network pharmacology based research into the effect and mechanism of Yinchenhao Decoction against Cholangiocarcinoma[J]. Chin Med, 2021, 16(1): 13. doi: 10.1186/s13020-021-00423-4
[15]	吕彦霖, 朱昌毫, 潘耀振, 等. 青藤碱对体外人胆管癌细胞的抑制作用[J]. 中成药, 2019, 41(11): 2601-2608. doi: 10.3969/j.issn.1001-1528.2019.11.010 Lv YL, Zhu CH, Pan YZ, et al. Inhibitory effect of sinsinine on human bile duct cancer cells in vitro[J]. Zhong Cheng Yao, 2019, 41(11): 2601-2608. doi: 10.3969/j.issn.1001-1528.2019.11.010
[16]	李彬彬, 付强, 王玉柱, 等. 葛根素对人胆管癌RBE细胞凋亡的影响[J]. 中华实验外科杂志, 2018, 35(1): 82-84. Li BB, Fu Q, Wang YZ, et al. Effect of puerarin on apoptosis of human bile duct carcinoma RBE cells[J]. Zhonghua Shi Yan Wai Ke Za Zhi, 2018, 35(1): 82-84.
[17]	康晓亮, 朱世高, 陈述海, 等. 抑瘤饮对胆管癌细胞增殖和凋亡的影响及机制[J]. 山东医药, 2018, 58(38): 16-19. https://www.cnki.com.cn/Article/CJFDTOTAL-SDYY201838005.htm Kang XL, Zhu SG, Chen SH, et al. Effect and mechanism of Yiyuyin on proliferation and apoptosis of bile duct cancer cells[J]. Shandong Yi Yao, 2018, 58(38): 16-19. https://www.cnki.com.cn/Article/CJFDTOTAL-SDYY201838005.htm
[18]	Hoffmeister-Wittmann P, Mock A, Nichetti F, et al. Bcl-xL as prognostic marker and potential therapeutic target in cholangiocarcinoma[J]. Liver Int, 2022, 42(12): 2855-2870. doi: 10.1111/liv.15392
[19]	朱建明, 邵志坚. 双氢青蒿素DHA诱导胆管癌细胞凋亡的分子机制研究[J]. 国际检验医学杂志, 2017, 38(16): 2183-2184, 2187. doi: 10.3969/j.issn.1673-4130.2017.16.003 Zhu JM, Shao ZJ. Study on the molecular mechanism of apoptosis induced by dihydroartemisinin DHA in bile duct cancer cells[J]. Guo Ji Jian Yan Yi Xue Za Zhi, 2017, 38(16): 2183-2184, 2187. doi: 10.3969/j.issn.1673-4130.2017.16.003
[20]	张金铎, 苏刚, 逯娅雯, 等. 莪术醇诱导胆管癌细胞凋亡和调控细胞周期的体外研究[J]. 兰州大学学报(医学版), 2018, 44(1): 65-70. https://www.cnki.com.cn/Article/CJFDTOTAL-LZYX201801012.htm Zhang JD, Su G, Lu YW, et al. In vitro study of apoptosis induced by curcumenol and cell cycle regulation in bile duct cancer cells[J]. Lanzhou Da Xue Xue Bao (Yi Xue Ban), 2018, 44(1): 65-70. https://www.cnki.com.cn/Article/CJFDTOTAL-LZYX201801012.htm
[21]	朱幼姗, 宋巍, 赵莹, 等. 蛇床子素对胆管癌QBC939细胞的诱导凋亡研究[J]. 广东医学, 2018, 39(4): 516-520. doi: 10.3969/j.issn.1001-9448.2018.04.007 Zhu YS, Song W, Zhao Y, et al. Study on apoptosis of QBC939 cells induced by saobitrin[J]. Guangdong Yi Xue, 2018, 39(4): 516-520. doi: 10.3969/j.issn.1001-9448.2018.04.007
[22]	赵冀安, 陈润芝, 武春燕, 等. JAK2/STAT3信号通路在肝内胆管细胞癌中的表达及预后[J]. 中国老年学杂志, 2023, 43(4): 805-809. doi: 10.3969/j.issn.1005-9202.2023.04.010 Zhao JA, Chen RZ, Wu CY, et al. Expression and prognosis of JAK2/STAT3 signaling pathway in intrahepatic cholangiocarcinoma[J]. Zhongguo Lao Nian Xue Za Zhi, 2023, 43(4): 805-809. doi: 10.3969/j.issn.1005-9202.2023.04.010
[23]	Zhu B, Zhao L, Liu Y, et al. Induction of phosphatase shatterproof 2 by evodiamine suppresses the proliferation and invasion of human cholangiocarcinoma[J]. Int J Biochem Cell Biol, 2019, 108: 98-110. doi: 10.1016/j.biocel.2019.01.012
[24]	邓秋媛, 刘志坤, 乔静. 紫草素调控PKM2/STAT3信号通路抑制RBE细胞转移的研究[J]. 毒理学杂志, 2020, 34(5): 385-388. https://www.cnki.com.cn/Article/CJFDTOTAL-WSDL202005009.htm Deng QY, Liu ZK, Qiao J. Inhibitory effect of shikonin on RBE cell metastasis by regulating PKM2/STAT3 signaling pathway[J]. Du Li Xue Za Zhi, 2020, 34(5): 385-388. https://www.cnki.com.cn/Article/CJFDTOTAL-WSDL202005009.htm
[25]	郑世勤, 王晓松, 陈双, 等. 大蒜素对TGF-β1诱导人胆管癌细胞上皮间质化的影响及机制[J]. 医学研究生学报, 2019, 32(2): 143-147. https://www.cnki.com.cn/Article/CJFDTOTAL-JLYB201902007.htm Zheng SQ, Wang XS, Chen S, et al. Effect and mechanism of epithelialization induced by TGF-β1 in human bile duct cancer cells [J]. Yi Xue Yan Jiu Sheng Xue Bao, 2019, 32(2): 143-147. https://www.cnki.com.cn/Article/CJFDTOTAL-JLYB201902007.htm
[26]	林雪晶, 刘春颖, 彭章晓, 等. 木香烃内酯对人胆管癌RBE细胞生物学行为的影响及其作用机制[J]. 中国肿瘤生物治疗杂志, 2018, 25(7): 687-692. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLSW201807005.htm Lin XJ, Liu CY, Peng ZX, et al. Effects of covanolactone on biological behavior of human cholangiocarcinoma RBE cells and its mechanism of action[J]. Zhongguo Zhong Liu Sheng Wu Zhi Liao Za Zhi, 2018, 25(7): 687-692. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLSW201807005.htm
[27]	马宏波, 蔺涛, 刘秀妃. 人参皂苷Rg3逆转人胆管癌细胞多药耐药性的实验研究[J]. 光明中医, 2018, 33(23): 3492-3495. https://www.cnki.com.cn/Article/CJFDTOTAL-GMZY201823019.htm Ma HB, Lin T, Liu XF. Experimental study on ginsenosides Rg3 reversing multidrug resistance in human bile duct cancer cells[J]. Guang Ming Zhong Yi, 2018, 33(23): 3492-3495. https://www.cnki.com.cn/Article/CJFDTOTAL-GMZY201823019.htm
[28]	刘秀妃, 蔺涛. 姜黄素逆转人胆管癌耐药细胞株QBC939/ADM的初步研究[J]. 亚太传统医药, 2018, 14(4): 12-14. https://www.cnki.com.cn/Article/CJFDTOTAL-YTCT201804007.htm Liu XF, Lin T. Preliminary study on curcumin reversal of human cholangiocarcinoma drug-resistant cell line QBC939/ADM[J]. Ya Tai Chuan Tong Yi Yao, 2018, 14(4): 12-14. https://www.cnki.com.cn/Article/CJFDTOTAL-YTCT201804007.htm
[29]	汪洋, 张筱凤, 汪静, 等. 细梗香草总皂苷联合5-氟尿嘧啶抗胆管癌作用及其机制研究[J]. 浙江中医药大学学报, 2018, 42(12): 989-995, 1005. https://www.cnki.com.cn/Article/CJFDTOTAL-BHON201812003.htm Wang Y, Zhang XF, Wang J, et al. Effect and mechanism of total saponins of Vanillaria chinensis combined with 5-fluorouracil on cholangiocarcinoma[J]. Zhejiang Zhong Yi Yao Da Xue Xue Bao, 2018, 42(12): 989-995, 1005. https://www.cnki.com.cn/Article/CJFDTOTAL-BHON201812003.htm
[30]	Fu Z, Ma K, Dong B, et al. The synergistic antitumor effect of Huaier combined with 5-Florouracil in human cholangiocarcinoma cells[J]. BMC Complement Altern Med, 2019, 19(1): 203.

[1]	HAN Baojin, TAN Ying, CAI Ruijuan, MAO Qiyuan, ZHANG Chuchu, ZHONG Yiwei, LIN Hongsheng. Wuzhi Wuyang——Traditional Chinese Medicine Prevention and Treatment of Malignant Tumor[J]. Cancer Research on Prevention and Treatment, 2025, 52(2): 93-97. DOI: 10.3971/j.issn.1000-8578.2025.24.1204
[2]	ZHAO Xiaoxue, WANG Zhongqi. Research Progress in Treatment of Malignant Tumors by Traditional Chinese Medicine Based on Exosomes[J]. Cancer Research on Prevention and Treatment, 2024, 51(2): 80-84. DOI: 10.3971/j.issn.1000-8578.2024.23.1152
[3]	WANG Runxi, YANG Shuhan, FANG Liyuan, WANG Yan, XIE Yi, LIU Suying, FANG Yuhang, ZHANG Ying. Traditional Chinese Medicine's "Yipingweiqi" Adjusts Homeostasis of Tumor Immune Microenvironment[J]. Cancer Research on Prevention and Treatment, 2023, 50(11): 1114-1120. DOI: 10.3971/j.issn.1000-8578.2023.23.0468
[4]	ZHANG Xue, YIN Junli, WANG Jiaxiang, SHI Wengui, JIAO Zuoyi. Research Progress on Anti-Tumor Mechanism of Theaflavins Natural Products[J]. Cancer Research on Prevention and Treatment, 2022, 49(8): 820-826. DOI: 10.3971/j.issn.1000-8578.2022.21.1292
[5]	HAN Jiaxuan, ZHAO Yun. Anti-tumor Mechanism of Sonodynamic Combined with Hyperthermia and Its Application in Tumor[J]. Cancer Research on Prevention and Treatment, 2022, 49(1): 78-82. DOI: 10.3971/j.issn.1000-8578.2022.21.1013
[6]	LIU Huihui, JIANG Liangqian, WANG Yujuan, LIU Guoxiang, JI Huanhuan, REN Junyi, LI Bing. Application Status of C-phycocyanin in Anti-tumor[J]. Cancer Research on Prevention and Treatment, 2018, 45(6): 420-424. DOI: 10.3971/j.issn.1000-8578.2018.17.1464
[7]	HOU Xiaoying, DU Hongzhi, YUAN Shengtao. Research Progress of Tumor Metabolism for Antitumor Drugs[J]. Cancer Research on Prevention and Treatment, 2017, 44(3): 231-235. DOI: 10.3971/j.issn.1000-8578.2017.03.015
[8]	SHAN Tie-ying, SONG Yong-hong, LI Mei-jie, ZHAO Yan-ming, SU An-ying, TANG Jun-min. Anti-tumor Mechanism of Human Dendrtic Cells by Lycium Bararum Polysaccharides[J]. Cancer Research on Prevention and Treatment, 2010, 37(01): 20-22. DOI: 10.3971/j.issn.1000-8578.2010.01.006
[9]	REN Jing, FENG Guo-nan, WANG Min-wei, SUN Li-xin. The Primary Study on the Anti-tumor Effect of Total Saponin of Solanum Lyratum Thunb[J]. Cancer Research on Prevention and Treatment, 2006, 33(04): 262-264. DOI: 10.3971/j.issn.1000-8578.3382
[10]	CHEN Lin-xiang, DAI Xin-yi, ZHOU Dai-han, et al, . Anti-hepatocarcinoma and inducing tumor cell apoptosis experiments of shentaoruangan pill in vivo[J]. Cancer Research on Prevention and Treatment, 2002, 29(06): 473-474. DOI: 10.3971/j.issn.1000-8578.1293

Cited By

Cited by

Periodical cited type(2)

1.	王逸，王强力，张甲，杨懿瑾，王盛. 结直肠癌肝转移患者组织中SUCNR1和YBX1的表达与临床病理特征及预后的关系. 国际肿瘤学杂志. 2025(03): 152-157 .
2.	郑雷，于宏伟，金丹雯，钱立勇. 老年结肠癌患者癌组织中COX-2、FOXA1和Cx43蛋白表达及与病理特征的关系. 中国老年学杂志. 2024(02): 291-293 .

Other cited types(1)

Get Citation

PDF

XML

Article views (2286) PDF downloads (1267) Cited by(3)

Turn off MathJax

Article Contents

Abstract

References

Mechanism Research Progress of Traditional Chinese Medicine in Prevention and Treatment of Cholangiocarcinoma

Abstract

References

Related Articles

Cited by

Periodical cited type(2)

Other cited types(1)

Catalog

Contact Us

Mechanism Research Progress of Traditional Chinese Medicine in Prevention and Treatment of Cholangiocarcinoma

Abstract

References

Related Articles

Cited by

Periodical cited type(2)

Other cited types(1)

Catalog

Contact Us

Export File

Citation

Format

Content